Reverse payment settlement agreements: trading one litigation headache for another
Reverse payment settlement agreements are under scrutiny in the US. Martin B Pavane and Lisa A Ferrari of Cohen Pontani Lieberman & Pavane LLP in New York explain why, and provide advice on how pharmaceutical companies can avoid investigation
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: